[go: up one dir, main page]

MX2017013170A - Formulaciones de fenilacetato de l-ornitina. - Google Patents

Formulaciones de fenilacetato de l-ornitina.

Info

Publication number
MX2017013170A
MX2017013170A MX2017013170A MX2017013170A MX2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A MX 2017013170 A MX2017013170 A MX 2017013170A
Authority
MX
Mexico
Prior art keywords
ornithine phenylacetate
patients
liver
oral formulations
formulations
Prior art date
Application number
MX2017013170A
Other languages
English (en)
Other versions
MX391167B (es
Inventor
Wang Laurene
Coffin Mark
Goodson Gary
RUETTIMANN Kenneth
Bernstein James
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX2017013170A publication Critical patent/MX2017013170A/es
Publication of MX391167B publication Critical patent/MX391167B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Algunas modalidades de la presente solicitud se refieren a formulaciones orales de fenilacetato de L-ornitina y a métodos para preparar las mismas. Estas formulaciones orales ofrecen una ruta alternativa de administración diferente de la administración intravenosa estándar de fenilacetato de L-ornitina para tratar hiperamonemia en pacientes que tiene varias enfermedades y trastornos hepáticos crónicos y agudos, por ejemplo, falla hepática aguda, cirrosis hepática, descompensación hepática, hipertensión portal, encefalopatía hepática, o pacientes con trastornos del ciclo de urea.
MX2017013170A 2015-04-20 2016-04-19 Formulaciones de fenilacetato de l-ornitina MX391167B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562150238P 2015-04-20 2015-04-20
US201562150676P 2015-04-21 2015-04-21
US201562211619P 2015-08-28 2015-08-28
US201562255300P 2015-11-13 2015-11-13
US201662276754P 2016-01-08 2016-01-08
PCT/US2016/028298 WO2016172112A1 (en) 2015-04-20 2016-04-19 Formulations of l-ornithine phenylacetate

Publications (2)

Publication Number Publication Date
MX2017013170A true MX2017013170A (es) 2018-04-11
MX391167B MX391167B (es) 2025-03-11

Family

ID=57144228

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013170A MX391167B (es) 2015-04-20 2016-04-19 Formulaciones de fenilacetato de l-ornitina
MX2022003855A MX2022003855A (es) 2015-04-20 2017-10-12 Formulaciones de fenilacetato de l-ornitina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003855A MX2022003855A (es) 2015-04-20 2017-10-12 Formulaciones de fenilacetato de l-ornitina.

Country Status (13)

Country Link
US (2) US20160338982A1 (es)
EP (2) EP3285756B1 (es)
JP (2) JP2018513171A (es)
KR (1) KR20180006904A (es)
CN (2) CN107708684A (es)
AU (2) AU2016252382A1 (es)
CA (1) CA2983146C (es)
DK (1) DK3285756T3 (es)
ES (1) ES2944311T3 (es)
HK (1) HK1251149A1 (es)
MX (2) MX391167B (es)
RU (1) RU2755904C2 (es)
WO (1) WO2016172112A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1824563T3 (pl) 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
SMT201700601T1 (it) 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
AU2016308641B2 (en) 2015-08-18 2022-02-03 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
RU2018113801A (ru) * 2015-11-13 2019-12-16 Осера Терапьютикс, Инк. Составы l-орнитин фенилацетата
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3621947A4 (en) 2017-05-11 2021-03-10 Ocera Therapeutics, Inc. L-ORNITHINE PHENYLACETATE MANUFACTURING PROCESSES
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2020227516A1 (en) 2019-05-09 2020-11-12 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy
PH12022550738A1 (en) * 2019-10-16 2023-05-08 Mallinckrodt Entpr Llc Dosages and uses of ornithine phenylacetate for treating hyperammonemia
EP4096647A1 (en) 2020-01-30 2022-12-07 Yeda Research and Development Co. Ltd Treating acute liver disease with tlr-mik inhibitors
WO2024261477A1 (en) 2023-06-20 2024-12-26 Yaqrit Limited Combination of tlr4 antagonist, ornithine and phenylacetate or phenylbutyrate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
PL1824563T3 (pl) * 2004-11-26 2010-07-30 Ucl Business Plc Kompozycje zawierające ornitynę i fenylooctan lub fenylomaślan do leczenia encefalopatii wątrobowej
AU2015221466B2 (en) * 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
SMT201700601T1 (it) * 2009-04-03 2018-03-08 Ocera Therapeutics Inc L-ornitina fenilacetato e metodi per la sua fabbricazione
AU2014250643B2 (en) * 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
MX2011013129A (es) * 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
CN103502203B (zh) * 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法

Also Published As

Publication number Publication date
KR20180006904A (ko) 2018-01-19
CN107708684A (zh) 2018-02-16
HK1251149A1 (zh) 2019-01-25
WO2016172112A1 (en) 2016-10-27
CN113599350A (zh) 2021-11-05
AU2016252382A1 (en) 2017-11-02
EP4205735A1 (en) 2023-07-05
MX2022003855A (es) 2023-03-02
EP3285756A4 (en) 2019-01-23
EP3285756B1 (en) 2023-02-22
DK3285756T3 (da) 2023-05-08
RU2017137643A3 (es) 2019-09-17
AU2021200740A1 (en) 2021-03-04
JP2018513171A (ja) 2018-05-24
RU2755904C2 (ru) 2021-09-22
JP2022101549A (ja) 2022-07-06
US20220184014A1 (en) 2022-06-16
US20160338982A1 (en) 2016-11-24
EP3285756A1 (en) 2018-02-28
CA2983146A1 (en) 2016-10-27
MX391167B (es) 2025-03-11
CA2983146C (en) 2023-09-12
ES2944311T3 (es) 2023-06-20
RU2017137643A (ru) 2019-05-20

Similar Documents

Publication Publication Date Title
MX2017013170A (es) Formulaciones de fenilacetato de l-ornitina.
MX2022001517A (es) Formulaciones de fenilacetato de l-ornitina.
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CO2018003168A2 (es) Moduladores de la expresión de kras
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
MX2017005236A (es) Profarmacos de carbidopa y l-dopa y metodos de uso.
MX377396B (es) Compuestos de azapiridona y usos de los mismos.
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112016018063A2 (pt) Dispositivo de fixação, e, método de fixação de um primeiro substrato em um segundo substrato
AR098168A1 (es) Formulación estable de insulina glulisina
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
CL2013003003A1 (es) Uso de fórmula infantil que comprende al menos una fuente de proteínas, una fuente de lípidos, una fuente de carbohidratos, con 1,6-1,85 g/100 kcal que sirve para preparar un medicamento útil en la prevención de la presión sanguínea elevada o de las enfermedades cardiovasculares.
MX2016015961A (es) Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas.
MX377579B (es) Composición farmacéutica oral de isotretinoína con dosis baja y su proceso de preparación.
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
MX2017009325A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
BR112016007238A2 (pt) tienouracilcarboxamidas cíclicas e sua utilização
BR112017001963A2 (pt) composição farmacêutica oral, seu processo de preparação e método de tratamento
MX2022004449A (es) Dosis y usos de fenilacetato de ornitina para el tratamiento de hiperamonemia.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
AR100028A1 (es) Composiciones nutricionales que contienen ácido estearidónico
MA40645A (fr) Préparation prébiotique à base d'inuline